A study of experimental combination of 2 drugs versus standard chemotherapy in patients with metastatic urothelial cancer

UVA Tracking #
Principal Investigator
Michael Devitt
Milos Lesevic
Contact Phone
Official Trial Title
An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer
Study Description

The UVA Cancer Center seeks adults ages 18 and over with previously untreated metastatic urothelial (bladder) cancer for a clinical trial. The purpose of this study is to evaluate a combination of 2 drugs vs standard chemotherapy in patients with metastatic urothelial cancer. Disease response and good and bad effects of the drug will be studied as part of this study. Study specific tests will be provided at no cost to you.

Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04223856


Compensation: $50 per visit. Reimbursement: Up to $175 for hotel stay.